BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38070147)

  • 1. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
    Kim AE; Lou KW; Giobbie-Hurder A; Chang K; Gidwani M; Hoebel K; Patel JB; Cleveland MC; Singh P; Bridge CP; Ahmed SR; Bearce BA; Liu W; Fuster-Garcia E; Lee EQ; Lin NU; Overmoyer B; Wen PY; Nayak L; Cohen JV; Dietrich J; Eichler A; Heist R; Krop I; Lawrence D; Ligibel J; Tolaney S; Mayer E; Winer E; Perrino CM; Summers EJ; Mahar M; Oh K; Shih HA; Cahill DP; Rosen BR; Yen YF; Kalpathy-Cramer J; Martinez-Lage M; Sullivan RJ; Brastianos PK; Emblem KE; Gerstner ER
    Neuro Oncol; 2024 May; 26(5):965-974. PubMed ID: 38070147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy.
    Kim AE; Lou KW; Giobbie-Hurder A; Chang K; Gidwani M; Hoebel K; Patel JB; Cleveland MC; Singh P; Bridge CP; Ahmed SR; Bearce BA; Liu W; Fuster-Garcia E; Lee EQ; Lin NU; Overmoyer B; Wen PY; Nayak L; Cohen JV; Dietrich J; Eichler A; Heist R; Krop I; Lawrence D; Ligibel J; Tolaney S; Mayer E; Winer E; Perrino CM; Summers EJ; Mahar M; Oh K; Shih HA; Cahill DP; Rosen BR; Yen YF; Kalpathy-Cramer J; Martinez-Lage M; Sullivan RJ; Brastianos PK; Emblem KE; Gerstner ER
    bioRxiv; 2023 Aug; ():. PubMed ID: 37693537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
    Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
    Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
    J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
    Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
    Metro G; Gili A; Signorelli D; De Toma A; Garaffa M; Galetta D; Economopoulou P; Friedlaender A; Jimenez B; Collazo-Lorduy A; Addeo A; Chiarini P; Costa C; Mountzios G; Roila F
    Clin Transl Oncol; 2021 Sep; 23(9):1818-1826. PubMed ID: 33728869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    Dagogo-Jack I; Lanfranchi M; Gainor JF; Giobbie-Hurder A; Lawrence DP; Shaw AT; Sullivan RJ
    J Immunother; 2017 Apr; 40(3):108-113. PubMed ID: 28221189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing available criteria for measuring brain metastasis response to immunotherapy.
    Qian JM; Mahajan A; Yu JB; Tsiouris AJ; Goldberg SB; Kluger HM; Chiang VLS
    J Neurooncol; 2017 May; 132(3):479-485. PubMed ID: 28275886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatments with immunotherapy in brain metastases patients.
    Henon C; Remon J; Hendriks LE
    Future Oncol; 2020 Aug; 16(23):1691-1705. PubMed ID: 32412817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
    Bhatia A; Birger M; Veeraraghavan H; Um H; Tixier F; McKenney AS; Cugliari M; Caviasco A; Bialczak A; Malani R; Flynn J; Zhang Z; Yang TJ; Santomasso BD; Shoushtari AN; Young RJ
    Neuro Oncol; 2019 Dec; 21(12):1578-1586. PubMed ID: 31621883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
    Metro G; Banna GL; Signorelli D; Gili A; Galetta D; Galli G; Economopoulou P; Roila F; Friedlaender A; Camerini A; Christopoulou A; Cantale O; De Toma A; Pizzutilo P; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Giannarelli D; Mountzios G; Addeo A
    J Immunother; 2020; 43(9):299-306. PubMed ID: 32991393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.